From lab to patient: Why European biotech is at a crossroads
Innovation only succeeds when it demonstrably creates value for both patients and the healthcare system. How can biotech and pharmaceutical players design their R&D strategies so that medical innovation reaches patients faster, more precisely, and in an affordable way? An interview with Jérôme Van Biervliet and Frank Hulstaert.
Latest stories
.jpg)
.jpg)
Modern science needs stronger infrastructure, and a new generation is rising to build it
Behind every cutting-edge experiment is a growing need for people who can build, manage, and future-proof the infrastructure that makes science possible. With its first ARISE fellow from EMBL, VIB is joining a European effort to train exactly that new generation of research technology professionals.
Germ-free mice and gut inflammation - Meet Lars Vereecke
As newly minted VIB Expert scientist and associate professor at UGent, Lars Vereecke leads the Host-Microbiota-Interaction lab at the VIB-UGent Center for Inflammation research. His lab established the first Belgian germ-free and gnotobiotic mouse facility and is part of the Ghent Gut Inflammation group. He is also a group leader at the Cancer Research Institute Ghent (CRIG).